Opexa Therapeutics CEO to Appear on The RedChip Money Report on Fox Business News

  Opexa Therapeutics CEO to Appear on The RedChip Money Report on Fox Business

Business Wire

THE WOODLANDS, Texas -- October 17, 2013

Opexa Therapeutics, Inc. (NASDAQ:OPXA), a biotechnology company developing
Tcelna^®, a novel T-cell immunotherapy for the treatment of multiple sclerosis
(MS), today announced that Opexa will be highlighted in an upcoming broadcast
of "The RedChip Money Report: Small Stocks Big Money," a nationally televised
financial program. The broadcast will include an interview with Opexa's
President and Chief Executive Officer, Neil K. Warma, and is scheduled to air
on Thursday, October 17th at 10:00 p.m. PDT on the Fox Business Network.

The interview will include a corporate update and financial highlights, as
well as provide an overview of Opexa's ongoing Phase IIb clinical trial for
Secondary Progressive MS, the Abili-T trial, being conducted in the United
States and Canada.

The "RedChip Money Report" segment from Fox Business will be made available on
the investor relations page of Opexa's website.

"The RedChip Money Report: Small Stocks Big Money"™ delivers insightful
commentary on small-cap investing, interviews with Wall Street analysts,
financial book reviews, as well as featured interviews with executives of
public companies. The show is hosted by Dave Gentry, a leading authority on
small-cap stocks and president of RedChip, an international small-cap research
firm and an Inc. 5000 company. Mr. Gentry has made multiple guest appearances
on both CNBC and Fox Business News and has been a consultant to hundreds of
public companies.

About Opexa

Opexa’s mission is to lead the field of Precision Immunotherapy™ by aligning
the interests of patients, employees and shareholders. The Company’s leading
therapy candidate, Tcelna^®, is a personalized T-cell immunotherapy that is in
a Phase IIb clinical development program (the Abili-T trial) for the treatment
of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the
patient’s peripheral blood, expanded ex vivo, and reintroduced into the
patients via subcutaneous injections. This process triggers a potent immune
response against specific subsets of autoreactive T-cells known to attack

About Multiple Sclerosis (MS)

MS is a chronic, inflammatory condition of the central nervous system and is
the most common, non-traumatic, disabling neurological disease in young
adults. It is estimated that approximately two million people have MS

While symptoms can vary, the most common symptoms of MS include blurred
vision, numbness or tingling in the limbs and problems with strength and
coordination. The relapsing forms of MS are the most common. The Secondary
Progressive form of MS represents about a third of the MS patient population.

About Tcelna

Tcelna^® is a potential personalized therapy that is under development to be
specifically tailored to each patient's disease profile. Tcelna is
manufactured using ImmPath™, Opexa's proprietary method for the production of
a patient-specific T-cell immunotherapy, which encompasses the collection of
blood from the MS patient, isolation of peripheral blood mononuclear cells,
generation of an autologous pool of myelin-reactive T-cells (MRTCs) raised
against selected peptides from myelin basic protein (MBP), myelin
oligodendrocyte glycoprotein (MOG) and proteolipid protein (PLP), and the
return of these expanded, irradiated T-cells back to the patient. These
attenuated T-cells are reintroduced into the patient via subcutaneous
injection to trigger a therapeutic immune system response.

Opexa is currently conducting a Phase IIb study of Tcelna. Named "Abili-T,"
the trial is a randomized, double-blind, placebo-controlled clinical study in
patients who demonstrate evidence of disease progression with or without
associated relapses. The trial is expected to enroll 180 patients at
approximately 30 leading clinical sites in the U.S. and Canada with each
patient receiving two annual courses of Tcelna treatment consisting of five
subcutaneous injections per year. The trial’s primary efficacy outcome is the
percentage of brain volume change (atrophy) at 24 months. Study investigators
will also measure several important secondary outcomes commonly associated
with MS, including disease progression as measured by the Expanded Disability
Status Scale (EDSS), annualized relapse rate and changes in disability as
measured by EDSS and the MS Functional Composite.

For more information visit the Opexa Therapeutics website at


Company Contact:
Karthik Radhakrishnan
Opexa Therapeutics, Inc.
Chief Financial Officer
Investor Relations:
The Trout Group
Adam Cutler
Press spacebar to pause and continue. Press esc to stop.